Company
Summit Therapeutics PLC
NASDAQ:SMMT
Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.
3 stories
Summit Therapeutics to Present at Canaccord Genuity Growth conference
Summit Therapeutics plc said on Friday its chief financial officer Erik Ostrowski will present at the Canaccord Genuity Growth Conference, 11 August at 1:30pm EDT in Boston